Fig. 2From: Safety and effectiveness of mepolizumab therapy in remission induction therapy for eosinophilic granulomatosis with polyangiitis: a retrospective studyComparison of the effectiveness of remission induction therapy over 6 months. A Decrease in BVAS. B Increase in VDI. C Reduction in peripheral eosinophil counts. D Concomitant CS dose. E Reduction rate of concomitant CS dose. F Percentage of cases by concomitant CS dose. BVAS, Birmingham Vasculitis Activity Score; VDI, Vasculitis Damage Index; CS, corticosteroid; MPZ, mepolizumab; IVCY, intravenous cyclophosphamide. P values were determined by the Wilcoxon rank-sum test. *P < 0.05: MPZ group vs. IVCY groupBack to article page